Honors Program
Honors Program: Theses
Date of this Version
2025
Document Type
Thesis
Citation
Trilling, John, Carly Goter, Anna Coffey, and Leo Ray. Boston Scientific Strategic Audit. Undergraduate Honors Thesis. University of Nebraska-Lincoln. 2025.
Abstract
Boston Scientific had a strong 2023, achieving 13.6% organic growth, $1.208 billion in profit, and maintaining a focus on employee satisfaction and sustainability. Recognized as a top workplace and leading innovator, the company is well-positioned for continued success. Its competitive edge stems from four key strengths. First, its top-tier innovation, driven by strong R&D investment, reinforces its credibility and specialization. Second, its skilled workforce accelerates product development. Third, its deep product lines foster extensive industry knowledge and creativity. Lastly, its logistical capabilities and strategic acquisitions have built a specialized, dominant portfolio. With a focused differentiation strategy, Boston Scientific competes with larger firms by leveraging its superior product depth and specialization. Operating within Cardiovascular and MedSurg solutions, the company’s R&D expands into related fields to drive portfolio efficiency. Strategic acquisitions further enhance its competitive standing, particularly in high-growth markets like cardiovascular solutions. Boston Scientific prioritizes investments in high-growth fields and regions to capture market share. Its history of successful acquisitions and targeted product expansion has fueled strong financial performance with a promising outlook. With its commitment to innovation and strategic investments, Boston Scientific is poised for sustained growth and profitability.
Comments
Copyright John Trilling, Carly Gorter, Anna Coffey, and Leo Ray 2025.